NO300548B1 - Fremgangsmåte for fremstilling av mometasonfuroatmonohydrat - Google Patents
Fremgangsmåte for fremstilling av mometasonfuroatmonohydrat Download PDFInfo
- Publication number
- NO300548B1 NO300548B1 NO930693A NO930693A NO300548B1 NO 300548 B1 NO300548 B1 NO 300548B1 NO 930693 A NO930693 A NO 930693A NO 930693 A NO930693 A NO 930693A NO 300548 B1 NO300548 B1 NO 300548B1
- Authority
- NO
- Norway
- Prior art keywords
- mometasone furoate
- water
- monohydrate
- furoate monohydrate
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 12
- 229960004123 mometasone furoate monohydrate Drugs 0.000 title abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 150000004682 monohydrates Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 229960002744 mometasone furoate Drugs 0.000 description 9
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- -1 acetone Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000004457 water analysis Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58023990A | 1990-09-10 | 1990-09-10 | |
| PCT/US1991/006249 WO1992004365A1 (en) | 1990-09-10 | 1991-09-06 | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO930693D0 NO930693D0 (no) | 1993-02-26 |
| NO930693L NO930693L (no) | 1993-02-26 |
| NO300548B1 true NO300548B1 (no) | 1997-06-16 |
Family
ID=24320279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO930693A NO300548B1 (no) | 1990-09-10 | 1993-02-26 | Fremgangsmåte for fremstilling av mometasonfuroatmonohydrat |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6180781B1 (de) |
| EP (1) | EP0548114B1 (de) |
| JP (1) | JPH0725789B2 (de) |
| KR (1) | KR960013445B1 (de) |
| CN (1) | CN1030920C (de) |
| AT (1) | ATE113604T1 (de) |
| AU (1) | AU663471B2 (de) |
| BG (1) | BG60755B2 (de) |
| CA (1) | CA2091360C (de) |
| CZ (1) | CZ281318B6 (de) |
| DE (2) | DE19875032I2 (de) |
| DK (1) | DK0548114T5 (de) |
| EE (1) | EE02962B1 (de) |
| ES (1) | ES2065701T3 (de) |
| FI (1) | FI111078B (de) |
| HK (1) | HK185996A (de) |
| HR (1) | HRP920383B1 (de) |
| HU (1) | HU213401B (de) |
| IE (1) | IE67056B1 (de) |
| IL (1) | IL99437A (de) |
| LU (1) | LU90366I2 (de) |
| MX (2) | MX9203396A (de) |
| MY (1) | MY106644A (de) |
| NL (1) | NL980012I2 (de) |
| NO (1) | NO300548B1 (de) |
| NZ (1) | NZ239711A (de) |
| OA (1) | OA09772A (de) |
| PH (1) | PH30443A (de) |
| PL (1) | PL165803B1 (de) |
| PT (1) | PT98905B (de) |
| SI (1) | SI9111497A (de) |
| TW (2) | TW229208B (de) |
| WO (1) | WO1992004365A1 (de) |
| YU (1) | YU48666B (de) |
| ZA (1) | ZA917148B (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU213401B (en) * | 1990-09-10 | 1997-06-30 | Schering Corp | Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it |
| PE44995A1 (es) | 1994-01-27 | 1995-12-18 | Schering Corp | Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| US5886200A (en) * | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| CN1059476C (zh) * | 1996-08-21 | 2000-12-13 | 邓维鹏 | 金黄色铝合金硒盐电解着色方法 |
| US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| CA2305256C (en) * | 1997-10-09 | 2005-05-17 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| MY133181A (en) * | 1998-09-10 | 2007-10-31 | Schering Corp | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| US7811606B2 (en) | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
| JP2007504123A (ja) * | 2003-08-29 | 2007-03-01 | ランバクシー ラボラトリーズ リミテッド | Ｉｖ型ホスホジエステラーゼの阻害剤 |
| US20070259874A1 (en) * | 2003-11-26 | 2007-11-08 | Palle Venkata P | Phosphodiesterase Inhibitors |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| WO2007031838A1 (en) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| US20070099883A1 (en) * | 2005-10-07 | 2007-05-03 | Cheryl Lynn Calis | Anhydrous mometasone furoate formulation |
| US20090221664A1 (en) | 2005-10-19 | 2009-09-03 | Abhijit Ray | Pharmaceutical compositions of muscarinic receptor antagonists |
| WO2007045980A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type iv inhibitors |
| CN100389121C (zh) * | 2005-12-09 | 2008-05-21 | 天津药业集团有限公司 | 糠酸莫美他松中间体21-羟的制备方法 |
| CN100436473C (zh) * | 2005-12-09 | 2008-11-26 | 天津药业集团有限公司 | 糠酸莫美他松中间体21-酯及制法 |
| DE102006034883A1 (de) * | 2006-07-25 | 2008-01-31 | Hermal Kurt Herrmann Gmbh & Co. Ohg | Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat |
| WO2008035316A2 (en) * | 2006-09-22 | 2008-03-27 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
| US20110021473A1 (en) * | 2006-09-22 | 2011-01-27 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
| US20080207659A1 (en) * | 2007-02-15 | 2008-08-28 | Asit Kumar Chakraborti | Inhibitors of phosphodiesterase type 4 |
| MX2009009793A (es) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. |
| US20110130403A1 (en) * | 2007-03-14 | 2011-06-02 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors |
| EP2111861A1 (de) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Zusammensetzungen von Phosphodiesterase-IV-Hemmern |
| TWI695723B (zh) | 2009-05-29 | 2020-06-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| PT105058B (pt) | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| US20140275517A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| CN107266518B (zh) * | 2016-04-08 | 2021-03-30 | 天津金耀集团有限公司 | 一种糠酸莫米松晶型及其制备方法 |
| CN107260671B (zh) * | 2016-04-08 | 2021-03-26 | 天津金耀集团有限公司 | 一种糠酸莫米松混悬鼻喷剂组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0057401B1 (de) * | 1981-02-02 | 1984-08-01 | Schering Corporation | Aromatische heterocyclische Steroidester, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten |
| US4783444A (en) | 1984-09-17 | 1988-11-08 | Schering Corporation | Antiglaucoma compositions and methods |
| US4808610A (en) * | 1986-10-02 | 1989-02-28 | Schering Corporation | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
| US4775529A (en) * | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
| HU213401B (en) * | 1990-09-10 | 1997-06-30 | Schering Corp | Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it |
-
1991
- 1991-09-06 HU HU9300685A patent/HU213401B/hu unknown
- 1991-09-06 PL PL91298223A patent/PL165803B1/pl unknown
- 1991-09-06 ES ES91915453T patent/ES2065701T3/es not_active Expired - Lifetime
- 1991-09-06 IL IL9943791A patent/IL99437A/en not_active IP Right Cessation
- 1991-09-06 CA CA002091360A patent/CA2091360C/en not_active Expired - Lifetime
- 1991-09-06 CZ CZ93383A patent/CZ281318B6/cs not_active IP Right Cessation
- 1991-09-06 WO PCT/US1991/006249 patent/WO1992004365A1/en active IP Right Grant
- 1991-09-06 JP JP3514768A patent/JPH0725789B2/ja not_active Expired - Lifetime
- 1991-09-06 DK DK91915453.4T patent/DK0548114T5/da active
- 1991-09-06 AU AU84974/91A patent/AU663471B2/en not_active Expired
- 1991-09-06 DE DE1991604991 patent/DE19875032I2/de active Active
- 1991-09-06 EP EP91915453A patent/EP0548114B1/de not_active Expired - Lifetime
- 1991-09-06 MX MX9203396A patent/MX9203396A/es unknown
- 1991-09-06 AT AT91915453T patent/ATE113604T1/de active
- 1991-09-06 KR KR1019930700702A patent/KR960013445B1/ko not_active IP Right Cessation
- 1991-09-06 DE DE69104991T patent/DE69104991T2/de not_active Expired - Lifetime
- 1991-09-09 TW TW080107102A patent/TW229208B/zh not_active IP Right Cessation
- 1991-09-09 IE IE315591A patent/IE67056B1/en not_active IP Right Cessation
- 1991-09-09 NZ NZ239711A patent/NZ239711A/en not_active IP Right Cessation
- 1991-09-09 YU YU149791A patent/YU48666B/sh unknown
- 1991-09-09 PT PT98905A patent/PT98905B/pt not_active IP Right Cessation
- 1991-09-09 SI SI9111497A patent/SI9111497A/sl unknown
- 1991-09-09 MX MX9100990A patent/MX9100990A/es unknown
- 1991-09-09 ZA ZA917148A patent/ZA917148B/xx unknown
- 1991-09-09 PH PH43072A patent/PH30443A/en unknown
- 1991-09-09 TW TW083106101A patent/TW272195B/zh not_active IP Right Cessation
- 1991-09-09 MY MYPI91001630A patent/MY106644A/en unknown
- 1991-09-10 CN CN91108910A patent/CN1030920C/zh not_active Expired - Lifetime
-
1992
- 1992-09-21 HR HRP-1497/91A patent/HRP920383B1/xx not_active IP Right Cessation
-
1993
- 1993-02-26 NO NO930693A patent/NO300548B1/no not_active IP Right Cessation
- 1993-03-09 FI FI931031A patent/FI111078B/fi not_active IP Right Cessation
- 1993-03-09 OA OA60348A patent/OA09772A/en unknown
-
1994
- 1994-02-24 BG BG98564A patent/BG60755B2/bg unknown
- 1994-11-21 EE EE9400388A patent/EE02962B1/xx unknown
-
1995
- 1995-04-17 US US08/422,479 patent/US6180781B1/en not_active Expired - Lifetime
-
1996
- 1996-10-03 HK HK185996A patent/HK185996A/xx not_active IP Right Cessation
-
1998
- 1998-03-12 NL NL980012C patent/NL980012I2/nl unknown
-
1999
- 1999-03-05 LU LU90366C patent/LU90366I2/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300548B1 (no) | Fremgangsmåte for fremstilling av mometasonfuroatmonohydrat | |
| US6127353A (en) | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions | |
| US5463116A (en) | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them | |
| JP6918824B2 (ja) | ２−［（２Ｓ）−１−アザビシクロ［２．２．２］オクタ−２−イル］−６−（３−メチル−１Ｈ−ピラゾール−４−イル）チエノ［３，２−ｄ］ピリミジン−４（３Ｈ）−オン半水和物の結晶形 | |
| JPH0714880B2 (ja) | エアゾル用に適するよう物理的に修正されたベクロメタソンジプロピオネ−ト | |
| WO2016150349A1 (zh) | 一种pci-32765晶型a的制备方法 | |
| JP3726291B2 (ja) | 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法 | |
| US4394319A (en) | Co-ordination compound of platinum | |
| CA2771011A1 (en) | Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine | |
| EP0000276B1 (de) | Neue kristalline Form des Benoxaprofens, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen die sie enthalten | |
| CN110590652B (zh) | 2-氨基-5-碘吡啶的合成方法 | |
| TWI680983B (zh) | 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體 | |
| KR20050033525A (ko) | 가바펜틴의 새로운 무수 결정질 형태 | |
| TWI727517B (zh) | 貝前列素-314d晶體及其製備方法 | |
| JPH0741495A (ja) | １４α−ヒドロキシ−４−アンドロステン−３，６，１７−トリオン水和物結晶及びその製造法 | |
| CN108017668A (zh) | 一种高晶型纯度磷酸肌酸钠四水半合物及其制备方法与用途 | |
| TW202227387A (zh) | 單水合曲前列環素晶體及其製備方法 | |
| NO169323B (no) | Fremgangsmaate til fremstilling av en steril enhetsdoseform, av 7-(dimetylaminometylen)-amino-9a-metoksymitosan i glass | |
| JPS6351145B2 (de) | ||
| CN113773249A (zh) | 索拉非尼游离碱晶型Form X及其制备方法 | |
| JPS63126880A (ja) | 金属ポルフイリン誘導体及びその製造法 | |
| NO178342B (no) | Krystallinsk etoposid-4'-fosfatdietanolat | |
| NO162021B (no) | Fremgangsmaate til fremstilling av krystallinsk 7-(dimetylaminometylen)amino-9a-metoksymitosan. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |